Top Page
Akari Therapeutics
(NASDAQ:AKTX)
Akari Therapeutics (AKTX) vs. S&P 500 (SPY)
Akari Therapeutics Business Overview & Revenue Model
Akari Therapeutics Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -13.00K | ― | ― | ― | ― | -19.20K | EBIT |
| -20.16M | -16.81M | -23.09M | -17.21M | -17.98M | -24.87M | EBITDA |
| -20.11M | -16.80M | -23.08M | -17.21M | -20.44M | -24.73M | Net Income Common Stockholders |
| -19.52M | -10.01M | -6.97M | -17.61M | -17.60M | -21.76M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 5.97M | 3.85M | 13.25M | 9.36M | 14.06M | 5.73M | Total Assets |
| 16.45M | 4.36M | 13.83M | 11.65M | 17.59M | 10.31M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -5.97M | -3.85M | -13.25M | -9.36M | -14.06M | -5.73M | Total Liabilities |
| 3.08M | 4.58M | 12.04M | 6.09M | 5.22M | 6.47M | Stockholders Equity |
| 13.38M | -229.00K | 1.79M | 5.55M | 12.38M | 3.84M |
| Cash Flow | Free Cash Flow | ||||
| -10.43M | -16.43M | -21.50M | -18.85M | -16.95M | -12.26M | Operating Cash Flow |
| -10.43M | -16.43M | -21.50M | -18.85M | -16.95M | -12.26M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 8.83M | 7.02M | 25.29M | 14.29M | 25.07M | 11.99M |
Akari Therapeutics Technical Analysis
Akari Therapeutics Risk Analysis
Akari Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $5.90B | 266.69 | 12.21% | ― | 40.80% | 100.62% | |
52 Neutral | $79.22M | ― | -62.38% | ― | 178.84% | -40.60% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
44 Neutral | $10.92M | ― | 291.66% | ― | ― | ― | |
42 Neutral | $196.87M | ― | 919.96% | ― | ― | ― | |
38 Underperform | $31.18M | ― | -596.70% | ― | ― | 9.74% | |
37 Underperform | $29.22M | ― | -45.37% | ― | ― | 72.12% |
Akari Therapeutics Corporate Events
Akari Therapeutics announced an updated corporate presentation that highlights their advancements in bi-functional ADCs for cancer treatment. The company is leveraging its novel discovery engine to develop innovative products like AKTX-101, with promising preclinical results and potential strategic partnerships, which could significantly enhance its market position and stakeholder value.
Akari Therapeutics has appointed Dr. Samir R. Patel as the permanent Chief Executive Officer, effective December 16, 2024, following his tenure as interim CEO since May 2024. Alongside this change, the company welcomed Abizer Gaslightwala as a new director, drawing on his extensive experience in the pharmaceutical sector. The board also acknowledged the resignation of director Michael Grissinger, who left without any disputes regarding the company’s operations.
Akari Therapeutics announced the appointment of Torsten Hombeck as the new Chief Financial Officer, effective December 16, 2024. Dr. Hombeck brings extensive experience in financial leadership within the healthcare and biopharmaceutical sectors, having served in similar roles at various companies including Aspira Women’s Health and Promethera Biosciences, which enhances Akari’s strategic positioning in the financial domain.
Akari Therapeutics announced a leadership change, with the termination of Wendy DiCicco’s role as Interim Chief Financial Officer. Samir Patel, the Interim CEO, has been appointed as Interim Principal Financial Officer and Principal Accounting Officer while the search for a permanent CFO is underway.
Akari Therapeutics has completed its merger with Peak Bio, enhancing its focus on developing therapies for autoimmune and inflammatory diseases. This strategic move also includes a $3.2 million private placement financing and a $50 million equity line of credit, potentially strengthening its financial standing post-merger. The combined entity aims to advance its innovative pipeline, particularly in Antibody Drug Conjugates and Geographic Atrophy therapies, ensuring the continuation of milestone achievements. These developments are crucial for Akari’s ongoing efforts to meet Nasdaq listing requirements.
Akari Therapeutics recently secured shareholder approval for its merger with Peak Bio, a significant milestone in the companies’ strategic alignment. The merger, characterized by a 50-50 equity exchange between the entities, aims to fortify their positions in the biotechnology sector, focusing on innovative therapies like Antibody Drug Conjugates (ADC) and Geographic Atrophy (GA) treatments. This merger is anticipated to resolve Akari’s Nasdaq listing concerns, paving the way for enhanced market presence and development in autoimmune and inflammatory disease therapies.